Abstract
Male breast cancer accounted for around 370 new cases in 2015 in the UK and about 20 cases per year are reported in Scotland. Most male breast cancers are sporadic and are associated with risk factors such as race, genetic predisposition, estrogen exposure and radiation exposure.
We report the case of a 67-year-old male with Grade III invasive ductal carcinoma and lymph node metastasis who underwent neoadjuvant chemotherapy prior to surgical treatment. In addition, we discuss the current rationale and evidence behind neoadjuvant chemotherapy for breast cancer, and the justification for providing this treatment in male breast cancer.
Due to the rarity of male breast cancer, it is difficult to determine its optimal management, but it would appear reasonable to extrapolate from studies on the management of female breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cancer Research UK. Available from: https://doi.org/www.cancerre-searchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer. Accessed May 2, 2018.
Yalaza M, Aydan İ, Bozer M. Male breast cancer. J Breast Health 2016;12:1–8.
Fazel MZ, Pitsinis V. Male breast cancer, in early breast cancer: from screening to multidisciplinary management. In: Benson JR, Gui GPH, Tuttle T, editors. 2013, CRC Press: USA.
Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005;104: 2359–64.
Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352(9132):930–42.
Rudlowski C. Male Breast Cancer. Breast Care 2008;3:183–9.
Fentiman IS. The biology of male breast cancer. Breast 2018;38:132–5.
Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer 2009; 16:136–40.
Pemmaraju N, Munsell MF, Hortobagyi GN, et al. Retrospective review of male breast cancer patients: Analysis of tamoxifen-related side-effects. Ann Oncol 2012;23:1471–4.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest and financial disclosure statements
The authors of this publication have no conflict of interest or financial relationships to disclose.
Rights and permissions
About this article
Cite this article
Choong, W.L., Pitsinis, V. Neoadjuvant Chemotherapy for Male Breast Cancer - “Pushing the Boundaries”. Hellenic J Surg 91, 102–104 (2019). https://doi.org/10.1007/s13126-019-0514-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13126-019-0514-2